ArticleThe Journal of infection2021
Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies.
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection.Evaluation & the health professions · 2021Pooled it
- Article
- Article
- Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Wellcome open research · 2023Article
- Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe.Frontiers in public health · 2023Review
- SARS-CoV-2 in immunocompromised individuals.Immunity · 2022Review
- SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.Haematologica · 2022Article
- COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.Nature reviews. Clinical oncology · 2022Review
- SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.Environmental research · 2022Review
- Suspected reinfections of SARS-COV-The Journal of infection · 2022Article
- Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences.Vaccines · 2022Review
- Modelling upper respiratory viral load dynamics of SARS-CoV-2.BMC medicine · 2022Article
- Modeling the evolution of SARS-CoV-2 under non-pharmaceutical interventions and testing.Evolution, medicine, and public health · 2022Article
- Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Article
- Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals.Infectious diseases and therapy · 2021Article
- Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study.BMC medicine · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34052242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.